Results 151 to 160 of about 116,692,355 (297)

Dual-input deep learning system for microbial identification from blood agar plates. [PDF]

PLoS One
Naito T, Takei S, Misawa S, Kuribara M, Tabe Y.   +4 more
europepmc   +1 more source

Liver Imaging in Precision Medicine [PDF]

EBioMedicine, 2018
Jiahong Dong, Xiaolong Qi
openaire   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT. [PDF]

J Nucl Med
Hofman MS, Corlett A, Pain C, Jackson P, Alipour R, Kong G, Wong AJN, Buteau J, Akhurst T, Fernando D, Siva S, Murphy DG.   +11 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Images in clinical medicine: vertebral artery dissection

Libyan Journal of Medicine, 2010
Laith Alrubaiy
doaj   +1 more source

First-in-Human Imaging Results of PHAROS: A Versatile High-Resolution TOF/DOI PET Scanner for Brain, Breast, and Extremity Imaging. [PDF]

J Nucl Med
Ko GB, Kim KY, Kang SK, Lee J, Jung R, Kwak DJ, Son JW, Shin SA, Ryoo HG, Kang YK, Kim S, Paeng JC, Byun MS, Shin JH, Cheon GJ, Kim YK, Choi H, Lee JS.   +17 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Data Management Workflow for FAIR Sharing of Bioimaging Datasets in Plasma Medicine. [PDF]

Sci Data
Ahmadi M, Wagner R, Bekeschus S, Becker MM.   +3 more
europepmc   +1 more source